Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received ...

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...
Oncology Nurse Advisor

Penpulimab Regimen Achieves Durable Control in Newly Diagnosed PCNSL

A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...
CURE

Mixed Cellularity Hodgkin Lymphoma: A Guide for Patients With Stage 1 Disease

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

Navigating a Canine Lymphoma Diagnosis: Science and Solutions

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.